AI Vendor Oversight and ICH E6(R3): Clinical Maestro at the R&D Procurement & Sourcing in Pharma Summit

Clinical Maestro will participate in the 10th R&D Procurement & Sourcing in Pharma Summit, taking place June 2–4, 2026 in Boston, bringing together procurement, outsourcing, sourcing, and vendor governance leaders from across pharma and biotech.

As part of the summit, Clinical Maestro will host an Executive Lunch Discussion focused on how AI is transforming clinical vendor oversight, governance, and operational decision-making under the evolving expectations of ICH E6(R3).

Executive Lunch Discussion

Superhuman Oversight: AI for Vendor Governancehshs

Revere Boston Common Hotel, Boston
June 3, 2026
12:20–1:20 PM EST

Speakers:

• Anca Copaescu, Founder & President, Clinical Maestro
• Sean Melville, VP Business Development, Clinical Maestro

Why Vendor Oversight Is Changing

Clinical outsourcing models are becoming increasingly complex. Sponsors are managing larger vendor ecosystems, more external partners, tighter timelines, and growing regulatory expectations across studies and programs.

At the same time, ICH E6(R3) is raising expectations for continuous, risk-based, and traceable vendor oversight.

Yet many organizations still rely on:

• fragmented spreadsheets
• disconnected governance processes
• static KPI reporting
• manual escalation workflows
• point-in-time oversight reviews

The result is often limited operational visibility, delayed risk identification, inconsistent governance, and growing oversight complexity.

From Reactive Oversight to Continuous Operational Intelligence

The Executive Lunch Discussion will explore how AI-enabled operational intelligence is helping organizations move beyond fragmented oversight models toward continuous vendor governance.

Topics will include:

• continuous vendor performance oversight
• KPI/KRI visibility
• operational risk monitoring
• governance workflows
• issue escalation management
• audit readiness
• AI-enabled decision support

The session will also discuss how leading organizations are beginning to operationalize ICH E6(R3) expectations through connected oversight models and centralized vendor governance processes.

How AI Is Transforming Clinical Vendor Governance

Artificial intelligence is rapidly changing how outsourcing and procurement teams manage vendor operations.

Instead of relying on disconnected reporting and manual reconciliation, organizations are increasingly adopting AI-enabled platforms that can:

• centralize vendor oversight data
• identify operational risks earlier
• improve governance visibility
• support faster decision-making
• strengthen inspection readiness

This shift is transforming vendor oversight from a reactive administrative process into a strategic operational capability.

Clinical Maestro Vision: AI-Enabled Vendor Oversight

Clinical Maestro Vision is an AI-enabled vendor oversight and governance solution designed to support continuous operational oversight aligned with ICH E6(R3).

The platform helps sponsors:

• centralize vendor governance activities
• monitor KPIs and KRIs continuously
• improve vendor performance visibility
• structure escalation workflows
• maintain oversight traceability
• strengthen operational governance across studies and vendors

Join Clinical Maestro at the Summit

Clinical Maestro is proud to participate in the R&D Procurement & Sourcing in Pharma Summit and contribute to the ongoing industry discussion around AI, vendor governance, operational intelligence, and the future of clinical outsourcing.

Join us for the Executive Lunch Discussion and connect with peers and industry leaders exploring the next generation of AI-enabled vendor oversight.

Frequently Asked Questions

What is the topic of Clinical Maestro’s Executive Lunch Discussion?
The session will focus on how AI is transforming clinical vendor management, vendor oversight, governance workflows, and operational decision-making under ICH E6(R3).

What is Clinical Maestro Vision?
Clinical Maestro Vision is an AI-enabled vendor oversight and governance platform designed to support continuous, risk-based oversight and operational intelligence across clinical outsourcing operations.

Why is ICH E6(R3) important for vendor oversight?
ICH E6(R3) increases expectations for continuous, traceable, and risk-based vendor oversight throughout the clinical trial lifecycle.

Who should attend the Executive Lunch Discussion?
The session is relevant for clinical outsourcing, procurement, vendor governance, clinical operations, and compliance leaders involved in vendor management and oversight.

How does AI improve vendor governance?
AI helps organizations centralize oversight data, automate governance workflows, improve KPI/KRI visibility, identify risks earlier, and support faster operational decisions.